A Study to Evaluate the Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies

Press/Media

Period15 Apr 2024

Media coverage

1

Media coverage

  • TitleA Study to Evaluate the Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies
    Media name/outletTB & Outbreaks Daily News
    Country/TerritoryUnited States
    Date15/04/24
    PersonsMark Lebwohl